Celgene’s Oral Mongersen Could Be Game-Changer In Crohn’s Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
New England Journal of Medicine editorial says that if Phase II results for Celgene’s oral antisense candidate mongersen (GED-0301) are confirmed, the drug’s durable effect “would be unprecedented and would represent a first step toward curing the disease.”